{
  "first_published_at": "2009-06-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087943", 
  "title": "Chloral hydrate (Welldorm) and Triclofos: not first-line options for insomnia", 
  "tags": "{\"parsed_therapeutic\": [\"paediatrics-neonatology\", \"psychiatry\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Paediatrics and neonatology\", \"Psychiatry\"]}", 
  "_document_number": 256, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "paediatrics-neonatology", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Chloral hydrate (Welldorm) and Triclofos:&#160;not first-line options for insomnia</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Chloral hydrate and Triclofos are not first-line options for insomnia-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Chloral hydrate and Triclofos are not first-line options for insomnia<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Chloral hydrate is an older drug which retains some limited clinical usage. The licensed products in the UK are Welldorm elixir (containing chloral hydrate) and Welldorm tablets (containing a precursor, chloral betaine). Triclofos is a closely related drug, which is metabolised in the liver to the same active metabolite as that formed from chloral. All three products have been licensed for many years for short-term treatment of insomnia.</p><p>Product information for these medicines has recently been changed to reflect current clinical practice where they are not first-line options for insomnia. The licensed indications have been amended to the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies.</p><p>The use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm tablets and Triclofos are not licensed for use in children. Welldorm elixir is licensed for use in adults and in children age 2 years or older. Treatment in children should be as an adjunct to behavioural therapy and sleep-hygiene management, and should not usually exceed 2 weeks.</p><p>The Summaries of Product Characteristics and patient leaflets are available for reference, and should be consulted for details of correct dose and other safety information.</p><ul>\r\n\t\t\t<li><a href=\"http://www.emc.medicines.org.uk/\" target=\"_blank\">Triclofos Summary of Product Characteristics</a></li>\r\n\t\t\t<li><a href=\"http://www.alphashow.co.uk/products.html\" target=\"_blank\">Welldorm Summary of Product Characteristics</a></li></ul><p>We are aware that chloral hydrate is being used for sedation in children, for example in intensive care units and before diagnostic procedures, whether as off-label use of licensed products or unlicensed medicines. General guidance on prescribers&rsquo; responsibilities when using a medicine off-label or using an unlicensed medicine has been published in the <a href=\"ssLINK/CON087990\" target=\"_blank\">April 2009 edition of Drug Safety Update</a>.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Welldorm and Triclofos are indicated only for the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies</li>\r\n\t\t\t\t<li>The use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm elixir can be used in children aged 2 years or older as an adjunct to behavioural therapy and sleep-hygiene management, usually for less than 2 weeks</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p><em>Article citation: Drug Safety Update June 2009, vol 2 issue 11: 3.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Chloral hydrate is an older drug which retains some limited clinical usage. The licensed products in the UK are Welldorm elixir (containing chloral hydrate) and Welldorm tablets (containing a precursor, chloral betaine). Triclofos is a closely related drug, which is metabolised in the liver to the same active metabolite as that formed from chloral. All three products have been licensed for many years for short-term treatment of insomnia.</p><p>Product information for these medicines has recently been changed to reflect current clinical practice where they are not first-line options for insomnia. The licensed indications have been amended to the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies.</p><p>The use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm tablets and Triclofos are not licensed for use in children. Welldorm elixir is licensed for use in adults and in children age 2 years or older. Treatment in children should be as an adjunct to behavioural therapy and sleep-hygiene management, and should not usually exceed 2 weeks.</p><p>The Summaries of Product Characteristics and patient leaflets are available for reference, and should be consulted for details of correct dose and other safety information.</p><ul>\r\n\t\t\t<li><a href=\"http://www.emc.medicines.org.uk/\" target=\"_blank\">Triclofos Summary of Product Characteristics</a></li>\r\n\t\t\t<li><a href=\"http://www.alphashow.co.uk/products.html\" target=\"_blank\">Welldorm Summary of Product Characteristics</a></li></ul><p>We are aware that chloral hydrate is being used for sedation in children, for example in intensive care units and before diagnostic procedures, whether as off-label use of licensed products or unlicensed medicines. General guidance on prescribers&#8217; responsibilities when using a medicine off-label or using an unlicensed medicine has been published in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON087990\" target=\"_blank\">April 2009 edition of Drug Safety Update</a>.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Welldorm and Triclofos are indicated only for the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies</li>\r\n\t\t\t\t<li>The use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm elixir can be used in children aged 2 years or older as an adjunct to behavioural therapy and sleep-hygiene management, usually for less than 2 weeks</li>\r\n\t\t\t</ul></div><p>&#160;</p><p><em>Article citation: Drug Safety Update June 2009, vol 2 issue 11: 3.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-06-01", 
  "date_last_modified": "2010-08-17", 
  "_assets": [], 
  "_item_id": 256, 
  "summary": "Chloral hydrate and Triclofos are not first-line options for insomnia", 
  "body": "Article date: June 2009\n\nChloral hydrate is an older drug which retains some limited clinical usage. The licensed products in the UK are Welldorm elixir (containing chloral hydrate) and Welldorm tablets (containing a precursor, chloral betaine). Triclofos is a closely related drug, which is metabolised in the liver to the same active metabolite as that formed from chloral. All three products have been licensed for many years for short-term treatment of insomnia.\n\nProduct information for these medicines has recently been changed to reflect current clinical practice where they are not first-line options for insomnia. The licensed indications have been amended to the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies.\n\nThe use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm tablets and Triclofos are not licensed for use in children. Welldorm elixir is licensed for use in adults and in children age 2 years or older. Treatment in children should be as an adjunct to behavioural therapy and sleep-hygiene management, and should not usually exceed 2 weeks.\n\nThe Summaries of Product Characteristics and patient leaflets are available for reference, and should be consulted for details of correct dose and other safety information.  \n  \n  * [Triclofos Summary of Product Characteristics](http://www.emc.medicines.org.uk/)  \n  * [Welldorm Summary of Product Characteristics](http://www.alphashow.co.uk/products.html)  \n  \nWe are aware that chloral hydrate is being used for sedation in children, for example in intensive care units and before diagnostic procedures, whether as off-label use of licensed products or unlicensed medicines. General guidance on prescribers’ responsibilities when using a medicine off-label or using an unlicensed medicine has been published in the [April 2009 edition of Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON087990).\n\nAdvice for healthcare professionals:  \n  \n  * Welldorm and Triclofos are indicated only for the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed, as an adjunct to non-pharmacological therapies  \n  * The use of hypnotics in children and adolescents is not generally recommended, and if used should be under the supervision of a specialist. Welldorm elixir can be used in children aged 2 years or older as an adjunct to behavioural therapy and sleep-hygiene management, usually for less than 2 weeks  \n  \n \n\nArticle citation: Drug Safety Update June 2009, vol 2 issue 11: 3.\n"
}